PDF
ePub
Citation
Print
Abstract
Purpose
To compare the outcomes in patients with diabetic macular edema (DME) treated with intravitreal dexamethasone implants and intravitreal bevacizumab injections.
Methods
A retrospective cohort study was designed using 66 patients with DME treated with intravitreal dexamethasone (n = 35; 35 eyes) and intravitreal bevacizumab (n = 31; 31 eyes). Post-treatment changes in hyperreflective foci in the inner and outer retina were characterized using optical coherence tomography, central macular thickness, outer limiting membrane, and photoreceptor inner segment-outer segment junctions. Visual acuities were analyzed 4 weeks after bevacizumab injections and 8 weeks after dexamethasone injections.
Results
Both groups showed a decrease in the number of hyperreflective foci after treatment: from 10.6 ± 11.8 to 6.3 ± 5.9 (p = 0.005) in the intravitreal dexamethasone implant group and from 11.6 ± 8.5 to 7.7 ± 6.7 (p < 0.001) in the intravitreal bevacizumab injection group. The mean central macular thickness in the dexamethasone group changed significantly from 586.8 µm to 297.7 µm after treatment and the visual acuity improved significantly from 0.33 logMAR to 0.38 logMAR after treatment (p < 0.001 and p = 0.018, respectively). The mean central macular thickness in the bevacizumab group showed a significant decrease from 467.1 µm to 353.2 µm after treatment (p < 0.001), but there was no significant change in the visual acuities: 0.34 logMAR to 0.32 logMAR after treatment (p = 0.464).
Figures and Tables
Figure 1
Changes in parameters of both groups after injection. (A) Visual acuity. (B) Intraocular pressure. (C) Spectral domain optical coherence tomography (SD-OCT) measurements of central macular thickness. (D) SD-OCT measurements of total number of hyperreflective foci. VA = visual acuity; logMAR = the log of the minimum angle resolution; IOP = intraocular pressure; CMT = central macular thickness; HRF = hyperreflective foci. *Categorical variables compared pre-treatment and post-treatment delta values of each parameter between bevacizumab group and dexamethasone group, using the independent t-test.
Figure 2
A 27-year-old male presented with diabetic macular edema injected dexamethasone implant. (A) Fundus photography at initial visit. Yellowish fibrinous materials are seen at the parafoveal area. The visual acuity is 20/200. (B) Fundus photography at eight weeks follow up. Yellowish fibrinous materials are much decreased. The visual acuity is 20/100. (C) Horizontal sectional image of optical coherence tomography (OCT) images at initial visit. The OCT shows sparse hyperreflective foci (arrows) distribution in the inner, outer and subretinal layers. Also subretinal fluid (SRF) is seen. (D) Horizontal sectional image of OCT images at eight weeks follow up. Hyperreflective foci are almost resolved and just small numbers (arrows) of hyperreflective foci remained. SRF is also nearly resolved.
Figure 3
A 57-year-old male presented with diabetic macular edema injected bevacizumab. (A) Fundus photography at initial visit. Retinal dot hemorrhages are seen at four quadrants. The visual acuity is 20/70. (B) Fundus photography at 4 weeks follow up. Previously seen retinal dot hemorrhages are much decreased. The visual acuity is 20/40. (C) Horizontal sectional image of optical coherence tomography (OCT) images at initial visit. The OCT shows sparse hyperreflective foci (arrows) distribution in the all retinal layers. (D) Horizontal sectional image of OCT images at four weeks follow up. Numbers of hyperreflective foci are decreased.
Figure 4
Comparison of changes in parameters of both groups after injection. Subretinal fluid, external limiting membrane, inner segment-outer segment junction changes after dexamethasone implant and injection groups for follow up eight and four weeks. SRF = subretinal fluid; ELM = external limiting membrane; ISOS = inner segment/outer segment. *Categorical variables compared pre-treatment and post-treatment delta values of each parameter between bevacizumab group and dexamethasone group, using the Fisher's exact test, and continuous variables with the independent t-test.
Figure 5
Correlation of pretreatment total number of hyperreflective foci and other parameters. (A) Correlation of central macular thickness and total number of hyperreflective foci before treatment in all patients of both groups. Central macular thickness and total number of hyperreflective foci showed weak positive correlation (p = 0.029, r = 0.189). (B) Change in visual acuity before and after treatment and total number of hyperreflective foci showed weak positive correlation (p = 0.014, r = 0.300). Change in central macular thickness before and after treatment and total number of hyperreflective foci showed weak positive correlation (p = 0.017, r = 0.293). Change in visual acuity before and after treatment and change in central macular thickness before and after treatment foci showed weak positive correlation (p = 0.030, r = 0.268). All correlations were analyzed with Spearman rank correlation. CMT = central macular thickness; HRF = hyperreflective foci; Delta VA = Change in visual acuity before and after treatment; Delta CMT = change in central macular thickness before and after treatment.
Table 1
Basic characteristics according to treatment group
Values are presented as mean ± standard deviation or number (%) unless otherwise indicated.
VA = visual acuity; logMAR = the log of the minimum angle resolution; HTN = hypertension; DMR = diabetic retinopathy; NPDR = non proliferative diabetic retinopathy; PDR = proliferative diabetic retinopathy; PRP = panretinal photocoagulation; VEGF = vascular endothelial growth factor; IOP = intraocular pressure; CMT = central macular thickness; HF = hyperreflective foci.
*Categorical variables compared using the chi-square test, and continuous variables with the independent t-test.
Table 2
Comparison of clinical parameters at pre and post-injection between groups
Values are presented as mean ± standard deviation or number (%).
VA = visual acuity; logMAR = the log of the minimum angle resolution; IOP = intraocular pressure; CMT = central macular thickness; HF = hyperreflective foci; SRF = subretinal fluid; ELM = external limiting membrane; EZ = ellipsoid zone.
*Categorical variables compared using the McNemar-Bowker test, and continuous variables with the paired t-test; †categorical variables compared pre-treatment and post-treatment delta values of each parameter between bevacizumab group and dexamethasone group, using the Fisher's exact test, and continuous variables with the independent t-test.
References
1. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998; 105:998–1003.
2. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009; 54:1–32.
3. Mathews MK, Merges C, McLeod DS, Lutty GA. Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy. Invest Ophthalmol Vis Sci. 1997; 38:2729–2741.
4. van Hecke MV, Dekker JM, Nijpels G, et al. Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn Study. Diabetologia. 2005; 48:1300–1306.
5. Chen TC, Cense B, Pierce MC, et al. Spectral domain optical coherence tomography: ultra-high speed, ultra-high resolution ophthalmic imaging. Arch Ophthalmol. 2005; 123:1715–1720.
6. Bolz M, Schmidt-Erfurth U, Deak G, et al. Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology. 2009; 116:914–920.
7. Imesch M, Wolf-Schnurrbusch U, Framme C, Wolf S. Small dense particles in the retina observable by spectral-domain optical coherence tomography in central retinal vein occlusion. Invest Ophthalmol Vis Sci. 2012; 53:2671.
8. Ogino K, Murakami T, Tsujikawa A, et al. Characteristics of optical coherence tomographic hyperreflective foci in retinal vein occlusion. Retina. 2012; 32:77–85.
9. Coscas G, De Benedetto U, Coscas F, et al. Hyperreflective dots: a new spectral-domain optical coherence tomography entity for follow-up and prognosis in exudative age-related macular degeneration. Ophthalmologica. 2013; 229:32–37.
10. Uji A, Murakami T, Nishijima K, et al. Association between hyperreflective foci in the outer retina, status of photoreceptor layer, and visual acuity in diabetic macular edema. Am J Ophthalmol. 2012; 153:710–717.
11. Framme C, Schweizer P, Imesch M, et al. Behavior of SD-OCT-detected hyperreflective foci in the retina of anti-VEGF-treated patients with diabetic macular edema. Invest Ophthalmol Vis Sci. 2012; 53:5814–5818.
12. Ota M, Nishijima K, Sakamoto A, et al. Optical coherence tomographic evaluation of foveal hard exudates in patients with diabetic maculopathy accompanying macular detachment. Ophthalmology. 2010; 117:1996–2002.
13. De Benedetto U, Sacconi R, Pierro L, et al. Optical coherence tomographic hyperreflective foci in early stages of diabetic retinopathy. Retina. 2015; 35:449–453.
14. Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004; 18:1450–1452.
15. Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res. 2007; 2007:95103.
16. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res. 2011; 30:343–358.
17. Vujosevic S, Bini S, Midena G, et al. Hyperreflective intraretinal spots in diabetics without and with nonproliferative diabetic retinopathy: an in vivo study using spectral domain OCT. J Diabetes Res. 2013; 2013:491835.
18. Avci R, Kaderli B. Intravitreal triamcinolone injection for chronic diabetic macular oedema with severe hard exudates. Graefes Arch Clin Exp Ophthalmol. 2006; 244:28–35.
19. Ciardella AP, Klancnik J, Schiff W, et al. Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study. Br J Ophthalmol. 2004; 88:1131–1136.
20. Khairallah M, Zeghidi H, Ladjimi A, et al. Primary intravitreal triamcinolone acetonide for diabetic massive macular hard exudates. Retina. 2005; 25:835–839.
21. Forstreuter F, Lucius R, Mentlein R. Vascular endothelial growth factor induces chemotaxis and proliferation of microglial cells. J Neuroimmunol. 2002; 132:93–98.
22. Hatz K, Ebneter A, Tuerksever C, et al. Repeated dexamethasone intravitreal implant for the treatment of diabetic macular oedema unresponsive to anti-VEGF therapy: outcome and predictive SD-OCT features. Ophthalmologica. 2018; 239:205–214.
23. Jeon S, Lee WK. Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates. Clin Ophthalmol. 2014; 8:1479–1486.
24. Schreur V, Altay L, van Asten F, et al. Hyperreflective foci on optical coherence tomography associate with treatment outcome for anti-VEGF in patients with diabetic macular edema. PLoS One. 2018; 13:e0206482.
25. Chatziralli IP, Sergentanis TN, Sivaprasad S. Hyperreflective foci as an independent visual outcome predictor in macular edema due to retinal vascular diseases treated with intravitreal dexamethasone or ranibizumab. Retina. 2016; 36:2319–2328.
27. Liu S, Wang D, Chen F, Zhang X. Hyperreflective foci in OCT image as a biomarker of poor prognosis in diabetic macular edema patients treating with Conbercept in China. BMC Ophthalmol. 2019; 19:157.
XML Download